Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4444-4446
10.1182/blood-2022-157713